MS Patients’ Likely Response to Interferon-Ī² May Be Evident in a Blood Biomarker
A new study underscoresĀ the variability of immune responses in different people with multiple sclerosis (MS) and suggests this heterogenityĀ affects responsesĀ to the commonly prescribed MS medication interferon-Ī², but blood biomarkers may exist that can help to determine those most likely to benefit from such treatment. The study,Ā “Cytokine profiles…